Study design for ARTEMIS Studies 1 and 2: Efficacy was evaluated in 2 multicenter, randomized, parallel-group, controlled, 20-month (including 8-month extended follow-up) studies of DURYSTA^® (bimatoprost intracameral implant) compared to twice-daily topical timolol (0.5%) drops in patients with OAG or OHT. IOP values obtained after initiation of non-study, IOP-lowering treatment were excluded from the analysis.^1,2

Primary efficacy endpoint: The study eye IOP at each hour was evaluated (Hours 0 and 2) at Weeks 2, 6, and 12.²